Evidence map›Paper›PMID 31727800›Full record

ArticleLife science alliance2019

MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy.

Mark Owyong, Jonathan Chou, Renske Je van den Bijgaart, Niwen Kong, Gizem Efe, Carrie Maynard, Dalit Talmi-Frank, Inna Solomonov, Charlotte Koopman, Elin Hadler-Olsen and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Mark OwyongDepartment of Anatomy, University of California, San Francisco, CA, USA.
Jonathan ChouDepartment of Anatomy, University of California, San Francisco, CA, USA.ORCID 0000-0003-1258-0391
Renske Je van den BijgaartDepartment of Anatomy, University of California, San Francisco, CA, USA.
Niwen KongDepartment of Anatomy, University of California, San Francisco, CA, USA.
Gizem EfeDepartment of Anatomy, University of California, San Francisco, CA, USA.
Carrie MaynardDepartment of Anatomy, University of California, San Francisco, CA, USA.
Dalit Talmi-FrankDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Inna SolomonovDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-2486-1350
Charlotte KoopmanDepartment of Anatomy, University of California, San Francisco, CA, USA.
Elin Hadler-OlsenDepartment of Anatomy, University of California, San Francisco, CA, USA.ORCID 0000-0001-8476-9439
Mark HeadleyDepartment of Pathology, University of California, San Francisco, CA, USA.
Charlene LinDepartment of Anatomy, University of California, San Francisco, CA, USA.
Chih-Yang WangDepartment of Anatomy, University of California, San Francisco, CA, USA.
Irit SagiDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Zena WerbDepartment of Anatomy, University of California, San Francisco, CA, USA zena.werb@ucsf.edu.
Vicki PlaksDepartment of Anatomy, University of California, San Francisco, CA, USA vicki.plaks@ucsf.edu.ORCID 0000-0002-4809-9252
University of California, San Francisco · USWeizmann Institute of Science · IL

Funding

Role of Metalloproteinases in Mammary Gland RemodelingR01CA057621 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 1993 to 2017
$9.0M
Integrative approach to heterogeneity in breast cancer metastasisU01CA199315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI, SPELLMAN, PAUL T. · 2016 to 2020
$3.2M
Role of GATA3 in transcriptional pathways suppressing breast cancer metastasisR01CA190851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2015 to 2019
$2.0M
(PQC4) Fate of cells disseminating from human breast cancer xenograftsR01CA180039 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA057621NCI NIH HHS R01 CA180039NCI NIH HHS R01 CA190851NCI NIH HHS U01 CA199315
6 · The paper itself

Abstract

Metastasis, the main cause of cancer-related death, has traditionally been viewed as a late-occurring process during cancer progression. Using the MMTV-PyMT luminal B breast cancer model, we demonstrate that the lung metastatic niche is established early during tumorigenesis. We found that matrix metalloproteinase 9 (MMP9) is an important component of the metastatic niche early in tumorigenesis and promotes circulating tumor cells to colonize the lungs. Blocking active MMP9, using a monoclonal antibody specific to the active form of gelatinases, inhibited endogenous and experimental lung metastases in the MMTV-PyMT model. Mechanistically, inhibiting MMP9 attenuated migration, invasion, and colony formation and promoted CD8

Indexed as

AnimalsAntibodiesBreast NeoplasmsCarcinogenesisCD8-Positive T-LymphocytesCell Line, TumorFemaleHEK293 CellsHumansLung NeoplasmsMammary Neoplasms, ExperimentalMatrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMiceMice, Inbred StrainsNeoplasm InvasivenessAntibodiesMatrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMMP9 protein, humanMmp9 protein, mouse

Identifiers

PMID31727800
PMCPMC6856766
OpenAlexW2988393258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.